FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE:BDX), a prominent global medical technology firm, today announced the global release of its new BD FACSDiscover™ S8 Cell Sorters. This launch aims to provide researchers in various scientific fields, including cell biology, cancer research, and immunology, with advanced tools to uncover insights beyond the capabilities of traditional flow cytometry.
The BD FACSDiscover™ S8 Cell Sorters incorporate BD CellView™ Image Technology and BD SpectralFX™ Technology, which were highlighted in the journal Science in 2022.
These technologies enable real-time imaging and spectral flow cytometry, offering researchers enhanced access and flexibility. The newly released three- and four-laser models join the previously launched five-laser instrument, broadening the range of options available to scientists for integrating these technologies into their laboratories.
According to Daniel Schraivogel, Ph.D., a research staff scientist at EMBL with extensive experience using the prototype, the new cell sorters maintain the same sorting speed and software capabilities as the five-laser unit, while offering scalability and ease of use.
The FACSDiscover™ S8 Cell Sorters allow for the real-time capture of complex biological and spatial insights, providing individual cell images and enabling the isolation of cells based on visual characteristics at high speeds. This streamlined workflow is designed to enhance the quality of sorts and samples, thereby increasing confidence in biological results and reducing time and costs for downstream applications.
Schraivogel notes that the imaging sorter facilitates better exploration of cell populations and validation of true single-cell gating and sorting, leading to improved cell quality and biological outcomes. This is particularly valuable in experiments where cellular debris and doublets can compromise results.
The BD FACSDiscover™ Cell Sorter family will be showcased at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, and is now available for order through local sales representatives.
BD is recognized for its contributions to the health sector by developing technologies and solutions to enhance patient care and advance medical research.
This article is based on a press release statement.
InvestingPro Insights
BD (Becton, Dickinson and Company) not only stands out for its innovative contributions to the medical technology landscape but also demonstrates a robust financial profile according to InvestingPro data. With a market capitalization of $70.22 billion and a revenue growth of 4.02% in the last twelve months as of Q1 2024, BD shows a steady expansion in the competitive healthcare equipment and supplies industry.
InvestingPro Tips indicate that BD has a notable track record of raising its dividend, now for 54 consecutive years, signaling a strong commitment to shareholder returns. This is particularly relevant for investors looking for stable income streams in the healthcare sector. Additionally, despite a high earnings multiple with a P/E ratio of 57.53, analysts predict profitability for the company this year, which may interest those focused on earnings growth potential.
The company's recent advancements, such as the launch of the BD FACSDiscover™ S8 Cell Sorters, underscore its role as a prominent player in healthcare innovation. This aligns with the InvestingPro Tip highlighting BD's status in the industry. Moreover, the company's stock has been trading near its 52-week low, which could present a potential entry point for investors considering the company's long-term growth prospects and its history of dividend reliability.
For more in-depth analysis and additional InvestingPro Tips on BD, which can further inform investment decisions, interested readers can explore https://www.investing.com/pro/BDX. There are 10 more tips available, providing a comprehensive view of the company's financial health and market position. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro for a deeper dive into financial metrics and expert insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.